fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Register Now For Tuesday’s (July 9) Tribe Public CEO Webinar Presentation and Q&A Event titled, “Exploring The Rapid Rise of Osteoarthritis”

By John F. Heerdink, Jr.

Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, announced that Eupraxia’s CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Event titled, “Exploring The Rapid Rise of Osteoarthritis.” Did you know that Osteoarthritis (OA) is the leading cause of disability in older adults? The US Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the US alone. This includes 14 million that suffer with knee pain or some form of disability. Knee OA is also associated with depression and loss of sleep, which can greatly affect quality of life.

The event is scheduled to begin at 8:30 am PT / 11:30 am ET on Tuesday, July 9, 2024.

To register to join the complimentary event, please visit Tribe Public at: EPRXJuly92024.TribePublic.com.

SPEAKER BACKGROUND?



At this event, you will be introduced to James A. Helliwell M.D. (pictured above) the Co-founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX). A board-certified Cardiac Anesthesiologist, he previously maintained a busy quaternary clinical and academic practice with a focus on cardiac transplantation and held a double tenure as President of the Anesthesiologists of BC.

Dr. Helliwell’s experience in the operating room and ICU instilled an appreciation for the value of precision drug delivery to achieve successful patient outcomes. This led him to create Eupraxia Pharmaceuticals, a company developing precision medicines in areas of high unmet medical need. In 2021, Eupraxia became the first biotech to successfully list exclusively on the Toronto Stock Exchange in almost 20 years. The company’s lead product candidate – a long-acting corticosteroid to treat osteoarthritis pain – is currently in Phase 2 clinical development.

Dr. Helliwell has also applied precision delivery to the medical device space. As Co-founder and CEO of Accuro Technologies, he invented Arthrotap® – a medical device to improve the accuracy of intra-articular injections. After successfully transacting on Accuro, he moved on to serve as Chair of the Board for Guidestar Medical Devices – a company focused on precision medicines delivery for the epidural space.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.

Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint and three of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a RESOLVE trial for treating eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company’s website at: www.eupraxiapharma.com.

About Tribe Public LLC

Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & in-person meeting events in the U.S. Tribe’s complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe’s FREE “Wish List” process. Visit Tribe Public’s Website to learn more: http://www.tribepublic.com.



YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us